Payment overview · 2025
General Payments
$669.38
18 reported records · 11 companies
Healthcare provider profile · identity verified
Joseph Daniel Mcguinness, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LEPANTO, AR · NPI 1225373749
Verified facts
What the public records show
CMS Open Payments records show Joseph Daniel Mcguinness, PA received $669.38 in general payments during 2025 across 18 reported records.
Gilead Sciences, Inc. accounted for 56.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Isentress by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $379.23 | 56.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.09 | 8.1% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $49.81 | 7.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.46 | 6.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.01 | 4.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.04 | 4.3% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $20.62 | 3.1% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $16.85 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.65 | 2.3% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.99 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.63 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $669.38 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $131.07 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $54.09 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $49.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 136 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
136 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 778 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 512 | 147 |
| Gabapentin | Gabapentin | 276 | 70 |
| Omeprazole | Omeprazole | 206 | 66 |
| Losartan Potassium | Losartan Potassium | 200 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 74 |
| Furosemide | Furosemide | 185 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 44 |
| Lisinopril | Lisinopril | 159 | 48 |
| Metformin Hcl | Metformin Hcl | 150 | 42 |
| Carvedilol | Carvedilol | 140 | 37 |
| Potassium Chloride | Potassium Chloride | 137 | 40 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 136 | 15 |
| Meloxicam | Meloxicam | 134 | 46 |
| Allopurinol | Allopurinol | 127 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 32 |
| Ozempic | Semaglutide | 110 | 27 |
| Trulicity | Dulaglutide | 108 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 31 |
| Jardiance | Empagliflozin | 100 | 36 |
| Famotidine | Famotidine | 92 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 88 | 23 |
| Tramadol Hcl | Tramadol Hcl | 86 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 23 |
| Trazodone Hcl | Trazodone Hcl | 77 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 24 |
| Descovy | Emtricitabine/Tenofov Alafenam | 75 | suppressed |
| Eliquis | Apixaban | 72 | 23 |
| Farxiga | Dapagliflozin Propanediol | 68 | 22 |
| Entresto | Sacubitril/Valsartan | 67 | 16 |
| Tivicay | Dolutegravir Sodium | 62 | suppressed |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Simvastatin | Simvastatin | 60 | 18 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Clonidine Hcl | Clonidine Hcl | 54 | 16 |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Spironolactone | Spironolactone | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 11 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 23 |
| Januvia | Sitagliptin Phosphate | 44 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 13 |
| Valacyclovir | Valacyclovir Hcl | 41 | 11 |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 13 |
| Ibuprofen | Ibuprofen | 35 | 17 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Levemir Flexpen | Insulin Detemir | 31 | 11 |
| Topiramate | Topiramate | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Nitroglycerin | Nitroglycerin | 29 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 22 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 12 |
| Ritonavir | Ritonavir | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | 12 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Naproxen | Naproxen | 23 | 15 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Glipizide | Glipizide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Isentress | Raltegravir Potassium | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | 11 |
| Darunavir | Darunavir | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prezista | Darunavir | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $669.38 · 18 records | Gilead Sciences, Inc. | Biktarvy, COMIRNATY, CeQur Simplicity, EGRIFTA, Epclusa, GEMTESA, JARDIANCE, JOURNAVX, Kerendia, MAVYRET, PENBRAYA, PIFELTRO, PREVNAR 20, RUKOBIA, TROGARZO, TRUMENBA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error